Venky's (India) Ltd
NSE:VENKEYS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Venky's (India) Ltd
NSE:VENKEYS
|
IN |
|
Adamant DRI Processing and Minerals Group
OTC:ADMG
|
CN |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
US |
|
A
|
Anhui Wantong Technology Co Ltd
SZSE:002331
|
CN |
Venky's (India) Ltd
Venky's India Ltd. engages in the production and sale of poultry products. The company is headquartered in Pune, Maharashtra. The firm's segments include Poultry and Poultry Products, Animal Health Products and Oilseed. The Poultry and Poultry Products segment produces and sells chicks, grownup commercial broiler and layer, processed chicken, SPF eggs, poultry feed and other miscellaneous poultry products. The Animal Health Products segment produces and sells medicines and other health products for birds. The Oilseed segment produces and sells edible refined soya oil and soya de-oiled cake. The firm has its growing and other manufacturing facilities across India and sells primarily in India.
Venky's India Ltd. engages in the production and sale of poultry products. The company is headquartered in Pune, Maharashtra. The firm's segments include Poultry and Poultry Products, Animal Health Products and Oilseed. The Poultry and Poultry Products segment produces and sells chicks, grownup commercial broiler and layer, processed chicken, SPF eggs, poultry feed and other miscellaneous poultry products. The Animal Health Products segment produces and sells medicines and other health products for birds. The Oilseed segment produces and sells edible refined soya oil and soya de-oiled cake. The firm has its growing and other manufacturing facilities across India and sells primarily in India.
Poultry Losses: Venky's reported significant losses in the poultry and poultry products segment for Q2 FY26 due to low realization on broiler chicks and birds, with profit margins falling sharply.
Seasonal & External Headwinds: Management cited festival timings, abnormal rains, flooding in northern India, and weak market prices as key drivers of poor poultry performance.
Animal Health Growth: The Animal Health Products (AHP) segment showed strong and stable growth, with revenue expected to surpass INR 370–380 crore for the year.
Raw Material Prices: Maize and soya prices have fallen well below MSP, with management expecting these lower input costs to positively impact margins from Q3 onward.
Improved Outlook: Poultry prices and realizations began improving in late October, leading management to expect a return to profitability in the second half of FY26.
Capacity Utilization: Utilization rates remain moderate (50–75%) across segments, with room to scale up quickly if demand improves.
Investor Concerns: Multiple investors expressed dissatisfaction over prolonged underperformance, questioning management on strategy, corporate governance, and capital allocation.
